Investigation of the effect of different flow-through cell designs on the release of diclofenac sodium SR tablets

Dissolution Technologies

Volumn 16, Issue 2, 2009, Pages 23-31

  Emara, Laila H ^a   Taha, Nesrin F ^a   Mursi, Nadia M ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69349093564     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT160209P23     Document Type: Article

References (29)

1. Banakar, U. V.; Block, L. H. Beyond bioavailability testing. Pharm. Technol. 1983, 7 (9), 107-117.
2. 2 in Comparison of Dissolution Profiles. Dissolution Technol. 2002, 9 (1) 18-22.
3. Banaker, U. V. Pharmaceutical Dissolution Testing, Marcel Dekker, Inc.: New York, 1992.
4. Shah, A. C.; Ochs, J. F. Design and evaluation of a rotating filter-stationary basket in vitro dissolution test apparatus. II. Continuous fluid flow system. J. Pharm. Sci. 1974, 63 (1), 110-113.
5. Kellaway, I. W.; Marriott, C. J. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1975, 64, 1162-1169.
6. Lin, S. L.; Menig, J.; Swartz, C. J. Comparative evaluation of various dissolution apparatus for capsule dosage forms. J. Pharm. Sci. 1970, 59 (7), 989-994.
7. Khan, K. A.; Rhodes, C. T. The production of tablets by direct compression. Can. J. Pharm. Sci. 1973, 8, 1-5.
8. Cox, D. C.; Furman, W. B. Systematic error associated with apparatus 2 of the USP dissolution test I: effects of physical alignment of the dissolution apparatus. J. Pharm. Sci. 1982, 71 (4), 451-452.
9. Moore, T. W.; Hamilton, J. F.; Kerner, C. M. Dissolution testing: limitations of the USP prednisone and salicylic acid calibrator tablets. Pharm. Forum 1995, 21, 1387-1396.
10. Qureshi, S. A.; McGilveray, I. J. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur. J. Pharm. Sci. 1999, 7, 249-258.
11. Qureshi, S.A., Shabnam, J., 2001. Cause of high variability in drug dissolution testing and its impact on setting tolerence. Eur. J. Pharm. Sci., 12, 271-276.
12. Zhang, G. H.; Vadino, W. A.; Yang, T. T.; Cho, W. P.; Chaudry, I. A. Evaluation of the flow-through cell dissolution apparatus: effects of flow rate, glass beads and tablet position on drug release from different type of tablets. Drug Dev. Ind. Pharm. 1994, 20 (13), 2063-2078.
13. Nicklasson, M.; Wennergren, B.; Lindberg, J.; Persson, C.; Ahlgren, R.; Palm, B.; Pettersson, A.; Wenngren, L. A collaborative in vitro dissolution study using the flow-through method. Int. J. Pharm. 1987, 37, 195-202.
14. Wennergren, B.; Lindberg, J.; Nicklasson, M.; Nilsson, G.; Nyberg, G.; Ahlgren, R.; Persson, C.; Palm, B. A collaprative in vitro dissolution study: comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. Int. J. Pharm. 1989, 53, 35-41.
15. Saleh, S. I.; Khider, S. H.; Aiache, J. M.; Beyssac, E.; Camacho, R. Comparative dissolution profiles of five internationally-available sustained-release diclofenac sodium dosage forms. S.T.P. Pharma Sci. 1992, 2 (3), 242-246.
16. Cammarn, S. R.; Sakr, A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int. J. Pharm. 2000, 201, 199-209.
17. Emara, L. H.; El-Menshawi, B. S.; Estefan, M. Y. In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations. Drug Dev. Ind. Pharm. 2000, 26 (3), 243-251.
18. Battachar, S. N.; Welsey, J. A.; Fioritto, A.; Martin, P. J.; Babu, S. R., Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus. Int. J. Pharm. 2002, 236, 135-143.
19. Bielen, N. Performance of USP calibrator tablets in flow-through cell apparatus. Int. J. Pharm. 2002, 233, 123-129.
20. Morihara, M.; Aoyagi, N.; Kaniwa, N.; Katori, N.; Kojim, S. Hydrodynamic flows around tablets in different pharmacopeial dissolution tests. Drug Dev. Ind. Pharm. 2002, 28 (6), 655-662.
21. Adeyeeye, C. M.; Li, P. K. Diclofenac Sodium. In Analytical Profiles of Drug Substances and Excipients; Florey, K., Ed.; Academic Press: New Jersey, 1990; Vol. 19, pp 123-144.
22. Kincl, M.; Vercer, F.; Veber, M. Characterization of factors affecting the release of low-solubility drug from prolonged release tablets. Anal. Chim. Acta 2004, 502, 107-113.
23. United States Pharmacopeia and National Formulary USP 23-NF 18; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 1995.
24. Badr, R. M. Improvement of Nifidepine Bioavailability in Oral Drug Delivery Systems. Ph.D. Thesis, Cairo University, Egypt, 2006.
25. Emara, L. H. Novartis Pharma, Egypt. Personal communication, 1996.
26. Moore, J. W.; Flanner, H. H. Mathematical comparison of dissolution profiles. Pharm. Technol. 1996, 20 (6), 64-67.
27. Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, 1997. http://www.fda.gov/cder/guidance/1713bp1.pdf (accessed Mar 19, 2009).
28. 2. Pharm. Res. 1998, 15 (6), 889-896.
29. SUPAC-MR: Modified-Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, September 1997. http://www.fda.gov/cder/guidance/1214fnl.pdf (accessed Mar 19, 2009).